AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics (ANGO) Tops Q3 EPS by 4c, Revenues Beat
April 7, 2020 7:02 AM EDTAngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.01, $0.04 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $69.8 million versus the consensus estimate of $68.55 million.
Third Quarter 2020 Financial Results
Net sales for the third quarter of fiscal 2020 were $69.8 million, an increase of 6.5% compared to the prior-year quarter. Excluding the impact of Asclera sales, which were discontinued during fiscal year 2019, net sales grew 9.3% year over year. Foreign currency translation did not have a significant impact on the Companys sales in the quarter.
Oncology net sales were $14.6 million, an... More